Drug Discovery
Compound screening analysis. ADMET prediction. Target identification.
(screenshot)
LIFE SCIENCES & BIOTECH
Drug discovery. Genomics. Clinical research. Computational biology moves fast — but compliance doesn’t sleep. Get the AI-powered analysis you need with the governance regulators require.
THE CHALLENGE
Patient data. Genomic sequences. Proprietary compounds. Clinical trial results. Your data is valuable, regulated, and a target.
Real compliance. Real governance. Real productivity gains.
HIPAA-ready — PHI stays protected. Access controls. Audit trails. Encryption at rest and in transit.
21 CFR Part 11 — Electronic records with full audit trails for FDA-regulated research.
Genomics at scale — Connect to sequencing pipelines, LIMS, and genomic databases. Query anything.
AI multiplier — Turn your bioinformaticians into 10x analysts. Natural language to SQL. Instant insights.
Multi-model flexibility — Use Claude for literature review. Local models for proprietary compound data.
Reproducible research — Same environment, every run. No dependency conflicts. No 'worked on my laptop.'
COMPUTATIONAL BIOLOGY
Compound screening analysis. ADMET prediction. Target identification.
Sequence analysis. Variant calling. Expression profiling.
Trial data analysis. Patient stratification. Outcome prediction.
Process optimization. Quality control analytics. Batch analysis.
Generate analysis reports. Document findings. Prepare submission packages.
Literature review. Patent analysis. Competitive intelligence.
Calliope gives life sciences teams the AI-powered analysis they need while maintaining the governance regulators demand. Query any data source. Build any report. Stay compliant.
See Healthcare Compliance